Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma
Status:
Not yet recruiting
Trial end date:
2028-04-10
Target enrollment:
Participant gender:
Summary
Subjects with papillary craniopharyngioma harboring a BRAF mutation will be treated with a
BRAF + MEK inhibitor (dabrafenib + trametinib) after informed consent. Study participants
will be administered oral dabrafenib and trametinib until maximal tumor volume reduction
assessed by MRI. Progression free survival, cognition, ophthalmologic status, hypothalamic
status and quality of life will be assessed 1 year after initiation of study treatment